Incyte Corporation vs Manulife Financial Corporation — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Manulife Financial Corporation trades at $43.84 (market cap $72.68B). The key difference: Manulife Financial Corporation is far larger — about 3× Incyte Corporation's market cap, and Manulife Financial Corporation pays a 3.1% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MFC | |
|---|---|---|
Market Cap | $24.54B | $72.68B |
Sector | Health | Financials |
52-Week High | $129.93 | $44.77 |
52-Week Low | $81.61 | $30.06 |
Enterprise Value | $20.04B | $67.84B |
Dividend Yield | — | 3.1% |
Trailing returns across standard periods
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →